<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02660242</url>
  </required_header>
  <id_info>
    <org_study_id>T1DX Mini-dose Exercise</org_study_id>
    <nct_id>NCT02660242</nct_id>
  </id_info>
  <brief_title>The Use of Mini-dose Glucagon to Prevent Exercise-induced Hypoglycemia in Type 1 Diabetes</brief_title>
  <official_title>The Use of Mini-dose Glucagon to Prevent Exercise-induced Hypoglycemia in Type 1 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jaeb Center for Health Research</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Xeris Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Jaeb Center for Health Research</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This project focuses on development of new strategy for the prevention of exercise-associated
      hypoglycemia using mini-dose glucagon.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objective of the protocol is to determine if the administration of mini-dose
      glucagon administered subcutaneously just before exercise produces better glucose stability
      than no adjustments for moderate intensity exercise in patients with Type 1 Diabetes (T1D).
      It will also be assessed whether mini-dose glucagon before exercise produces better glucose
      stability than basal insulin reductions or extra carbohydrate consumption.

      This is a randomized, 4-way crossover trial. The trial will include 16 participants who
      complete the study.

      Each participant will undergo four aerobic exercise sessions (in random order), with
      different strategies for glucose regulation:

        -  Control Trial: Fasted exercise, no basal insulin reduction

        -  Strategy 1: Fasted exercise, basal insulin reduction only (50% reduction in basal rate
           at 60 minutes before exercise, for the duration of the exercise)

        -  Strategy 2: Fasted exercise, no basal adjustment + pre-exercise glucose tabs (buccal
           route-40 grams in total )

        -  Strategy 3: Fasted exercise, no basal adjustment + pre-exercise mini-dose glucagon (sc)

      In all 4 sessions, aerobic exercise will be performed in the fasted state (before a
      standardized meal) for 45 minuets at ~50-55% of the participant's per-determined aerobic
      capacity. The participant's pump will be blinded during the control trial, strategy 1, and
      strategy 3 and an injection of saline will be given during the control trial and strategy 1
      so that participant is blinded to strategy.

      The primary outcome for this study will be the glycemic response during exercise and early
      recovery.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2016</start_date>
  <completion_date type="Actual">February 15, 2017</completion_date>
  <primary_completion_date type="Actual">February 15, 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Glycemic Response During Exercise and Early Recovery</measure>
    <time_frame>0 to 75 minutes following exercise initiation (0, 5, 10, 15, 25, 35, 45, 50, 55, 60, 75 min)</time_frame>
    <description>Comparison of glycemic response (from blood glucose) during exercise and early recovery between each exercise strategy.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Hypoglycemia (&lt;70 mg/dL) During Exercise and Early Recovery</measure>
    <time_frame>0 to 75 minutes following exercise initiation</time_frame>
    <description>Comparison of occurrence of hypoglycemia (&lt;70 mg/dL from blood glucose) during exercise and early recovery between each exercise strategy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Hyperglycemia (≥250 mg/dL) During Exercise and Early Recovery</measure>
    <time_frame>0 to 75 minutes following exercise initiation</time_frame>
    <description>Comparison of occurrence of hyperglycemia (≥250 mg/dL from blood glucose) during exercise and early recovery between each exercise strategy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Continuous Glucose Monitor (CGM) Metrics During Late Recovery - Nadir Glucose</measure>
    <time_frame>90 min after the standard meal until 1200 noon the day after each exercise session</time_frame>
    <description>Comparison of nadir glucose from CGM between the exercise strategies.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CGM Metrics During Late Recovery - Peak Glucose</measure>
    <time_frame>90 min after the standard meal until 1200 noon the day after each exercise session</time_frame>
    <description>Comparison of peak glucose from CGM between the exercise strategies.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CGM Metrics During Late Recovery - Mean Glucose</measure>
    <time_frame>90 min after the standard meal until 1200 noon the day after each exercise session</time_frame>
    <description>Comparison of mean glucose from CGM between the exercise strategies.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CGM Metrics During Late Recovery - Coefficient of Variation</measure>
    <time_frame>90 min after the standard meal until 1200 noon the day after each exercise session</time_frame>
    <description>Comparison of the coefficient of variation from CGM between the exercise strategies.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CGM Metrics During Late Recovery - Time &lt; 54 mg/dL</measure>
    <time_frame>90 min after the standard meal until 1200 noon the day after each exercise session</time_frame>
    <description>Comparison of percentage of time &lt; 54 mg/dL from CGM between the exercise strategies.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CGM Metrics During Late Recovery - Time &lt; 70 mg/dL</measure>
    <time_frame>90 min after the standard meal until 1200 noon the day after each exercise session</time_frame>
    <description>Comparison of percentage of time &lt; 70 mg/dL from CGM between the exercise strategies.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CGM Metrics During Late Recovery - Time in Range (70-180 mg/dL)</measure>
    <time_frame>90 min after the standard meal until 1200 noon the day after each exercise session</time_frame>
    <description>Comparison of percentage of time in range (70-180 mg/dL) from CGM between the exercise strategies.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CGM Metrics During Late Recovery - Time &gt; 180 mg/dL</measure>
    <time_frame>90 min after the standard meal until 1200 noon the day after each exercise session</time_frame>
    <description>Comparison of percentage of time &gt; 180 mg/dL from CGM between the exercise strategies.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CGM Metrics During Late Recovery - Time &gt; 250 mg/dL</measure>
    <time_frame>90 min after the standard meal until 1200 noon the day after each exercise session</time_frame>
    <description>Comparison of percentage of time &gt; 250 mg/dL from CGM between the exercise strategies.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Diabetes Mellitus, Type 1</condition>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>No basal insulin adjustment, no carbohydrate intake (until glucose drops &lt;70 mg/dL).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Basal insulin reduction</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Basal insulin reduction to 50% five minutes before the start of exercise.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Glucose Tabs</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Dextrose tabs orally (20 grams) five minutes before the start of exercise and at 30 minutes of exercise (total 40 grams).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>G-Pen Mini™ (glucagon injection)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Glucagon (150 µg) five minutes before the start of exercise (SQ-abdomen).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>G-Pen Mini™ (glucagon injection)</intervention_name>
    <description>Glucagon (150 µg) 5 minutes before the start of exercise (SQ-abdomen).</description>
    <arm_group_label>G-Pen Mini™ (glucagon injection)</arm_group_label>
    <other_name>mini-dose glucagon</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Glucose Tabs</intervention_name>
    <description>Dextrose tabs orally (20 grams) 5 minutes before the start of exercise and at 30 minutes of exercise (total 40 grams).</description>
    <arm_group_label>Glucose Tabs</arm_group_label>
    <other_name>over-the-counter oral glucose tablets</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Basal Insulin Reduction</intervention_name>
    <description>Basal insulin reduction to 50% 5 minutes before the start of exercise.</description>
    <arm_group_label>Basal insulin reduction</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Clinical diagnosis of presumed autoimmune type 1 diabetes, receiving daily insulin

          2. Age 18-&lt;65 years

          3. Duration of T1D ≥ 2 years

          4. Random C-peptide &lt; 0.6 ng/ml

          5. Using continuous subcutaneous insulin infusion (CSII; insulin pump) for at least 6
             months, with no plans to discontinue pump use during the study

          6. Exercises regularly, i.e. ≥30 minutes moderate or more vigorous aerobic activity X ≥3
             times/week

          7. Body mass index (BMI) &lt;30 kg/m2

          8. Females must meet one of the following criteria:

               -  Of childbearing potential and not currently pregnant or lactating, and agrees to
                  use an accepted contraceptive regimen as described in the study procedure manual
                  throughout the entire duration of the study; or

               -  Of non-childbearing potential, defined as a female who has had a hysterectomy or
                  tubal ligation, is clinically considered infertile or is in a menopausal state
                  (at least 1 year without menses)

          9. In good general health with no conditions that could influence the outcome of the
             trial, and in the judgment of the investigator is a good candidate for the study based
             on review of available medical history, physical examination and clinical laboratory
             evaluations

         10. Willing to adhere to the protocol requirements for the duration of the study

         11. Must be enrolled in the T1D Exchange clinic registry or willing to join the registry

        Exclusion Criteria:

          1. One or more severe hypoglycemic episodes in the past 12 months (as defined by an
             episode that required third party assistance for treatment)

          2. Active diabetic retinopathy (proliferative diabetic retinopathy or vitreous hemorrhage
             in past 6 months) that could potentially be worsened by exercise protocol

          3. Peripheral neuropathy with insensate feet

          4. Cardiovascular autonomic neuropathy with inappropriate heart rate response to exercise

          5. Use of non-insulin anti-diabetic medications

          6. Use of beta-blockers

          7. Use of agents that affect hepatic glucose production such as beta adrenergic agonists,
             xanthine derivatives

          8. Use of Pramlintide

          9. Currently following a very low calorie or other weight-loss diet

         10. Participation in other studies involving administration of an investigational drug or
             device within 30 days or 5 half-lives, whichever is longer, before screening for the
             current study or planning to participate in another such study during participation in
             the current study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Riddell, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>York University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Michael Rickels, M.D., M.S.</last_name>
    <role>Study Chair</role>
    <affiliation>University of Pennsylvania</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Howard Wolpert, M.D.</last_name>
    <role>Study Chair</role>
    <affiliation>Joslin Diabetes Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Stephanie DuBose, M.P.H</last_name>
    <role>Principal Investigator</role>
    <affiliation>Jaeb Center for Health Research</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Joslin Diabetes Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Chu L, Hamilton J, Riddell MC. Clinical management of the physically active patient with type 1 diabetes. Phys Sportsmed. 2011 May;39(2):64-77. doi: 10.3810/psm.2011.05.1896. Review.</citation>
    <PMID>21673486</PMID>
  </reference>
  <reference>
    <citation>West DJ, Morton RD, Bain SC, Stephens JW, Bracken RM. Blood glucose responses to reductions in pre-exercise rapid-acting insulin for 24 h after running in individuals with type 1 diabetes. J Sports Sci. 2010 May;28(7):781-8. doi: 10.1080/02640411003734093.</citation>
    <PMID>20496226</PMID>
  </reference>
  <reference>
    <citation>Brazeau AS, Rabasa-Lhoret R, Strychar I, Mircescu H. Barriers to physical activity among patients with type 1 diabetes. Diabetes Care. 2008 Nov;31(11):2108-9. doi: 10.2337/dc08-0720. Epub 2008 Aug 8.</citation>
    <PMID>18689694</PMID>
  </reference>
  <reference>
    <citation>Rabasa-Lhoret R, Bourque J, Ducros F, Chiasson JL. Guidelines for premeal insulin dose reduction for postprandial exercise of different intensities and durations in type 1 diabetic subjects treated intensively with a basal-bolus insulin regimen (ultralente-lispro). Diabetes Care. 2001 Apr;24(4):625-30.</citation>
    <PMID>11315820</PMID>
  </reference>
  <reference>
    <citation>Campbell MD, Walker M, Trenell MI, Jakovljevic DG, Stevenson EJ, Bracken RM, Bain SC, West DJ. Large pre- and postexercise rapid-acting insulin reductions preserve glycemia and prevent early- but not late-onset hypoglycemia in patients with type 1 diabetes. Diabetes Care. 2013 Aug;36(8):2217-24. doi: 10.2337/dc12-2467. Epub 2013 Mar 20.</citation>
    <PMID>23514728</PMID>
  </reference>
  <reference>
    <citation>Stenerson M, Cameron F, Payne SR, Payne SL, Ly TT, Wilson DM, Buckingham BA. The impact of accelerometer use in exercise-associated hypoglycemia prevention in type 1 diabetes. J Diabetes Sci Technol. 2015 Jan;9(1):80-5. doi: 10.1177/1932296814551045. Epub 2014 Sep 17.</citation>
    <PMID>25231116</PMID>
  </reference>
  <reference>
    <citation>Tsalikian E, Mauras N, Beck RW, Tamborlane WV, Janz KF, Chase HP, Wysocki T, Weinzimer SA, Buckingham BA, Kollman C, Xing D, Ruedy KJ; Diabetes Research In Children Network Direcnet Study Group. Impact of exercise on overnight glycemic control in children with type 1 diabetes mellitus. J Pediatr. 2005 Oct;147(4):528-34.</citation>
    <PMID>16227041</PMID>
  </reference>
  <reference>
    <citation>Tanenberg RJ, Newton CA, Drake AJ. Confirmation of hypoglycemia in the &quot;dead-in-bed&quot; syndrome, as captured by a retrospective continuous glucose monitoring system. Endocr Pract. 2010 Mar-Apr;16(2):244-8. doi: 10.4158/EP09260.CR.</citation>
    <PMID>19833577</PMID>
  </reference>
  <reference>
    <citation>Campbell MD, Walker M, Trenell MI, Luzio S, Dunseath G, Tuner D, Bracken RM, Bain SC, Russell M, Stevenson EJ, West DJ. Metabolic implications when employing heavy pre- and post-exercise rapid-acting insulin reductions to prevent hypoglycaemia in type 1 diabetes patients: a randomised clinical trial. PLoS One. 2014 May 23;9(5):e97143. doi: 10.1371/journal.pone.0097143. eCollection 2014.</citation>
    <PMID>24858952</PMID>
  </reference>
  <reference>
    <citation>Taplin CE, Cobry E, Messer L, McFann K, Chase HP, Fiallo-Scharer R. Preventing post-exercise nocturnal hypoglycemia in children with type 1 diabetes. J Pediatr. 2010 Nov;157(5):784-8.e1. doi: 10.1016/j.jpeds.2010.06.004. Epub 2010 Jul 21.</citation>
    <PMID>20650471</PMID>
  </reference>
  <reference>
    <citation>Riddell MC, Bar-Or O, Ayub BV, Calvert RE, Heigenhauser GJ. Glucose ingestion matched with total carbohydrate utilization attenuates hypoglycemia during exercise in adolescents with IDDM. Int J Sport Nutr. 1999 Mar;9(1):24-34.</citation>
    <PMID>10036339</PMID>
  </reference>
  <reference>
    <citation>Robertson K, Riddell MC, Guinhouya BC, Adolfsson P, Hanas R; International Society for Pediatric and Adolescent Diabetes. ISPAD Clinical Practice Consensus Guidelines 2014. Exercise in children and adolescents with diabetes. Pediatr Diabetes. 2014 Sep;15 Suppl 20:203-23. doi: 10.1111/pedi.12176.</citation>
    <PMID>25182315</PMID>
  </reference>
  <reference>
    <citation>Camacho RC, Galassetti P, Davis SN, Wasserman DH. Glucoregulation during and after exercise in health and insulin-dependent diabetes. Exerc Sport Sci Rev. 2005 Jan;33(1):17-23. Review.</citation>
    <PMID>15640716</PMID>
  </reference>
  <reference>
    <citation>Oskarsson PR, Lins PE, Wallberg Henriksson H, Adamson UC. Metabolic and hormonal responses to exercise in type 1 diabetic patients during continuous subcutaneous, as compared to continuous intraperitoneal, insulin infusion. Diabetes Metab. 1999 Dec;25(6):491-7.</citation>
    <PMID>10633873</PMID>
  </reference>
  <reference>
    <citation>Haymond MW, Schreiner B. Mini-dose glucagon rescue for hypoglycemia in children with type 1 diabetes. Diabetes Care. 2001 Apr;24(4):643-5.</citation>
    <PMID>11315823</PMID>
  </reference>
  <reference>
    <citation>Diabetes Research in Children Network (DirecNet) Study Group, Tsalikian E, Kollman C, Tamborlane WB, Beck RW, Fiallo-Scharer R, Fox L, Janz KF, Ruedy KJ, Wilson D, Xing D, Weinzimer SA. Prevention of hypoglycemia during exercise in children with type 1 diabetes by suspending basal insulin. Diabetes Care. 2006 Oct;29(10):2200-4.</citation>
    <PMID>17003293</PMID>
  </reference>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>January 6, 2016</study_first_submitted>
  <study_first_submitted_qc>January 18, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 21, 2016</study_first_posted>
  <results_first_submitted>June 6, 2018</results_first_submitted>
  <results_first_submitted_qc>July 11, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">August 7, 2018</results_first_posted>
  <last_update_submitted>February 28, 2020</last_update_submitted>
  <last_update_submitted_qc>February 28, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 3, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>T1D</keyword>
  <keyword>Type 1 Diabetes</keyword>
  <keyword>Mini-dose Glucagon</keyword>
  <keyword>Adults</keyword>
  <keyword>Exercise</keyword>
  <keyword>Hypoglycemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
    <mesh_term>Hypoglycemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glucagon</mesh_term>
    <mesh_term>Glucagon-Like Peptide 1</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>April 14, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/42/NCT02660242/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>February 24, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/42/NCT02660242/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>MIni-dose Glucagon Crossover Trial</title>
          <description>Each participant will undergo four aerobic exercise sessions (in random order) of a) a Control Trial: Fasted exercise, no basal insulin reduction; b) Strategy 1: Fasted exercise, basal insulin reduction only (50% reduction in basal rate five minutes before exercise, for the duration of the exercise); c) Strategy 2: Fasted exercise, no basal adjustment + pre-exercise and mid-exercise glucose tabs (buccal route-40 grams in total); d) Strategy 3: Fasted exercise, no basal adjustment + pre-exercise mini-dose glucagon (sc). Each period includes 0-165 minutes in the lab and the participant continues to wear a continuous glucose monitor during the afternoon, overnight, and through noon the following day.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Control</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Basal Insulin Reduction</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Glucose Tabs</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="16">16 participants were randomized but only 15 completed all 4 periods.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Glucagon Injection</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="16">16 participants were randomized but only 15 completed all 4 periods.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Entire Study Population</title>
          <description>Includes all patients who completed the crossover trial.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="15"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30" lower_limit="25" upper_limit="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Type 1 Diabetes Duration, Continuous</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22" lower_limit="14" upper_limit="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>HbA1c</title>
          <units>%</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6.8" lower_limit="6.5" upper_limit="7.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index (BMI)</title>
          <units>kg/m^2</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24" lower_limit="23" upper_limit="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>VO2Max</title>
          <units>mL/kg/min</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42" lower_limit="35" upper_limit="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Glycemic Response During Exercise and Early Recovery</title>
        <description>Comparison of glycemic response (from blood glucose) during exercise and early recovery between each exercise strategy.</description>
        <time_frame>0 to 75 minutes following exercise initiation (0, 5, 10, 15, 25, 35, 45, 50, 55, 60, 75 min)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Control</title>
            <description>No basal insulin adjustment, no carbohydrate intake (until glucose drops &lt;70 mg/dL).</description>
          </group>
          <group group_id="O2">
            <title>Basal Insulin Reduction</title>
            <description>Basal insulin reduction to 50% 5 minutes before the start of exercise.</description>
          </group>
          <group group_id="O3">
            <title>Glucose Tabs</title>
            <description>Dextrose tabs orally (20 grams) 5 minutes before the start of exercise and at 30 minutes of exercise (total 40 grams).</description>
          </group>
          <group group_id="O4">
            <title>G-Pen Mini™ (Glucagon Injection)</title>
            <description>Glucagon (150 µg) 5 minutes before the start of exercise (SQ-abdomen).</description>
          </group>
        </group_list>
        <measure>
          <title>Glycemic Response During Exercise and Early Recovery</title>
          <description>Comparison of glycemic response (from blood glucose) during exercise and early recovery between each exercise strategy.</description>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="15"/>
                <count group_id="O4" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Plasma Glucose Concentration (End of Exercise)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86" spread="30"/>
                    <measurement group_id="O2" value="85" spread="25"/>
                    <measurement group_id="O3" value="174" spread="59"/>
                    <measurement group_id="O4" value="161" spread="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Plasma Glucose Concentration (End Early Recovery)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90" spread="34"/>
                    <measurement group_id="O2" value="92" spread="34"/>
                    <measurement group_id="O3" value="222" spread="66"/>
                    <measurement group_id="O4" value="163" spread="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>The mini-dose glucagon (MDG) condition was compared with each of the conditions. In the event that exercise was terminated early due to glucose &lt;70 mg/dL and the participant was treated for hypoglycemia (or if participant was treated for hypoglycemia during early recovery [prior to the meal]), the nadir glucose value was carried forward through the end of early recovery.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed model w/ repeated measures to account for correlation from cross-over design and multiple measures, adjusting for baseline glucose and period.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Hypoglycemia (&lt;70 mg/dL) During Exercise and Early Recovery</title>
        <description>Comparison of occurrence of hypoglycemia (&lt;70 mg/dL from blood glucose) during exercise and early recovery between each exercise strategy.</description>
        <time_frame>0 to 75 minutes following exercise initiation</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Control</title>
            <description>No basal insulin adjustment, no carbohydrate intake (until glucose drops &lt;70 mg/dL).</description>
          </group>
          <group group_id="O2">
            <title>Basal Insulin Reduction</title>
            <description>Basal insulin reduction to 50% 5 minutes before the start of exercise.</description>
          </group>
          <group group_id="O3">
            <title>Glucose Tabs</title>
            <description>Dextrose tabs orally (20 grams) 5 minutes before the start of exercise and at 30 minutes of exercise (total 40 grams).</description>
          </group>
          <group group_id="O4">
            <title>G-Pen Mini™ (Glucagon Injection)</title>
            <description>Glucagon (150 µg) 5 minutes before the start of exercise (SQ-abdomen).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Hypoglycemia (&lt;70 mg/dL) During Exercise and Early Recovery</title>
          <description>Comparison of occurrence of hypoglycemia (&lt;70 mg/dL from blood glucose) during exercise and early recovery between each exercise strategy.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="15"/>
                <count group_id="O4" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.99</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted for subject effect, exercise session, and baseline blood glucose</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Hyperglycemia (≥250 mg/dL) During Exercise and Early Recovery</title>
        <description>Comparison of occurrence of hyperglycemia (≥250 mg/dL from blood glucose) during exercise and early recovery between each exercise strategy.</description>
        <time_frame>0 to 75 minutes following exercise initiation</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Control</title>
            <description>No basal insulin adjustment, no carbohydrate intake (until glucose drops &lt;70 mg/dL).</description>
          </group>
          <group group_id="O2">
            <title>Basal Insulin Reduction</title>
            <description>Basal insulin reduction to 50% 5 minutes before the start of exercise.</description>
          </group>
          <group group_id="O3">
            <title>Glucose Tabs</title>
            <description>Dextrose tabs orally (20 grams) 5 minutes before the start of exercise and at 30 minutes of exercise (total 40 grams).</description>
          </group>
          <group group_id="O4">
            <title>G-Pen Mini™ (Glucagon Injection)</title>
            <description>Glucagon (150 µg) 5 minutes before the start of exercise (SQ-abdomen).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Hyperglycemia (≥250 mg/dL) During Exercise and Early Recovery</title>
          <description>Comparison of occurrence of hyperglycemia (≥250 mg/dL from blood glucose) during exercise and early recovery between each exercise strategy.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="15"/>
                <count group_id="O4" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.15</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted for subject effect, exercise session, and baseline blood glucose</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Continuous Glucose Monitor (CGM) Metrics During Late Recovery - Nadir Glucose</title>
        <description>Comparison of nadir glucose from CGM between the exercise strategies.</description>
        <time_frame>90 min after the standard meal until 1200 noon the day after each exercise session</time_frame>
        <population>Included data were limited to periods with at least 12 hours of CGM data.</population>
        <group_list>
          <group group_id="O1">
            <title>Control</title>
            <description>No basal insulin adjustment, no carbohydrate intake (until glucose drops &lt;70 mg/dL).</description>
          </group>
          <group group_id="O2">
            <title>Basal Insulin Reduction</title>
            <description>Basal insulin reduction to 50% five minutes before the start of exercise.</description>
          </group>
          <group group_id="O3">
            <title>Glucose Tabs</title>
            <description>Dextrose tabs orally (20 grams) five minutes before the start of exercise and at 30 minutes of exercise (total 40 grams).</description>
          </group>
          <group group_id="O4">
            <title>G-Pen Mini™ (Glucagon Injection)</title>
            <description>Glucagon (150 µg) five minutes before the start of exercise (SQ-abdomen).</description>
          </group>
        </group_list>
        <measure>
          <title>Continuous Glucose Monitor (CGM) Metrics During Late Recovery - Nadir Glucose</title>
          <description>Comparison of nadir glucose from CGM between the exercise strategies.</description>
          <population>Included data were limited to periods with at least 12 hours of CGM data.</population>
          <units>mg/dL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="13"/>
                <count group_id="O3" value="13"/>
                <count group_id="O4" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45" lower_limit="39" upper_limit="60"/>
                    <measurement group_id="O2" value="44" lower_limit="40" upper_limit="56"/>
                    <measurement group_id="O3" value="49" lower_limit="40" upper_limit="55"/>
                    <measurement group_id="O4" value="51" lower_limit="40" upper_limit="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.99</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Accounted for correlation due to cross-over design and adjusted for exercise session</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>CGM Metrics During Late Recovery - Peak Glucose</title>
        <description>Comparison of peak glucose from CGM between the exercise strategies.</description>
        <time_frame>90 min after the standard meal until 1200 noon the day after each exercise session</time_frame>
        <population>Included data were limited to periods with at least 12 hours of CGM data.</population>
        <group_list>
          <group group_id="O1">
            <title>Control</title>
            <description>No basal insulin adjustment, no carbohydrate intake (until glucose drops &lt;70 mg/dL).</description>
          </group>
          <group group_id="O2">
            <title>Basal Insulin Reduction</title>
            <description>Basal insulin reduction to 50% 5 minutes before the start of exercise.</description>
          </group>
          <group group_id="O3">
            <title>Glucose Tabs</title>
            <description>Dextrose tabs orally (20 grams) 5 minutes before the start of exercise and at 30 minutes of exercise (total 40 grams).</description>
          </group>
          <group group_id="O4">
            <title>G-Pen Mini™ (Glucagon Injection)</title>
            <description>Glucagon (150 µg) 5 minutes before the start of exercise (SQ-abdomen).</description>
          </group>
        </group_list>
        <measure>
          <title>CGM Metrics During Late Recovery - Peak Glucose</title>
          <description>Comparison of peak glucose from CGM between the exercise strategies.</description>
          <population>Included data were limited to periods with at least 12 hours of CGM data.</population>
          <units>mg/dL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="13"/>
                <count group_id="O3" value="13"/>
                <count group_id="O4" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="241" lower_limit="216" upper_limit="279"/>
                    <measurement group_id="O2" value="239" lower_limit="222" upper_limit="299"/>
                    <measurement group_id="O3" value="267" lower_limit="211" upper_limit="331"/>
                    <measurement group_id="O4" value="269" lower_limit="235" upper_limit="281"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.43</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Accounted for correlation due to cross-over design and adjusted for exercise session</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>CGM Metrics During Late Recovery - Mean Glucose</title>
        <description>Comparison of mean glucose from CGM between the exercise strategies.</description>
        <time_frame>90 min after the standard meal until 1200 noon the day after each exercise session</time_frame>
        <population>Included data were limited to periods with at least 12 hours of CGM data.</population>
        <group_list>
          <group group_id="O1">
            <title>Control</title>
            <description>No basal insulin adjustment, no carbohydrate intake (until glucose drops &lt;70 mg/dL).</description>
          </group>
          <group group_id="O2">
            <title>Basal Insulin Reduction</title>
            <description>Basal insulin reduction to 50% 5 minutes before the start of exercise.</description>
          </group>
          <group group_id="O3">
            <title>Glucose Tabs</title>
            <description>Dextrose tabs orally (20 grams) 5 minutes before the start of exercise and at 30 minutes of exercise (total 40 grams).</description>
          </group>
          <group group_id="O4">
            <title>G-Pen Mini™ (Glucagon Injection)</title>
            <description>Glucagon (150 µg) 5 minutes before the start of exercise (SQ-abdomen).</description>
          </group>
        </group_list>
        <measure>
          <title>CGM Metrics During Late Recovery - Mean Glucose</title>
          <description>Comparison of mean glucose from CGM between the exercise strategies.</description>
          <population>Included data were limited to periods with at least 12 hours of CGM data.</population>
          <units>mg/dL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="13"/>
                <count group_id="O3" value="13"/>
                <count group_id="O4" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="129" lower_limit="114" upper_limit="144"/>
                    <measurement group_id="O2" value="139" lower_limit="127" upper_limit="149"/>
                    <measurement group_id="O3" value="130" lower_limit="117" upper_limit="148"/>
                    <measurement group_id="O4" value="147" lower_limit="126" upper_limit="161"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.16</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Accounted for correlation due to cross-over design and adjusted for exercise session</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>CGM Metrics During Late Recovery - Coefficient of Variation</title>
        <description>Comparison of the coefficient of variation from CGM between the exercise strategies.</description>
        <time_frame>90 min after the standard meal until 1200 noon the day after each exercise session</time_frame>
        <population>Included data were limited to periods with at least 12 hours of CGM data</population>
        <group_list>
          <group group_id="O1">
            <title>Control</title>
            <description>No basal insulin adjustment, no carbohydrate intake (until glucose drops &lt;70 mg/dL).</description>
          </group>
          <group group_id="O2">
            <title>Basal Insulin Reduction</title>
            <description>Basal insulin reduction to 50% 5 minutes before the start of exercise.</description>
          </group>
          <group group_id="O3">
            <title>Glucose Tabs</title>
            <description>Dextrose tabs orally (20 grams) 5 minutes before the start of exercise and at 30 minutes of exercise (total 40 grams).</description>
          </group>
          <group group_id="O4">
            <title>G-Pen Mini™ (Glucagon Injection)</title>
            <description>Glucagon (150 µg) 5 minutes before the start of exercise (SQ-abdomen).</description>
          </group>
        </group_list>
        <measure>
          <title>CGM Metrics During Late Recovery - Coefficient of Variation</title>
          <description>Comparison of the coefficient of variation from CGM between the exercise strategies.</description>
          <population>Included data were limited to periods with at least 12 hours of CGM data</population>
          <units>percentage</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="13"/>
                <count group_id="O3" value="13"/>
                <count group_id="O4" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32" lower_limit="29" upper_limit="42"/>
                    <measurement group_id="O2" value="35" lower_limit="33" upper_limit="40"/>
                    <measurement group_id="O3" value="36" lower_limit="32" upper_limit="42"/>
                    <measurement group_id="O4" value="33" lower_limit="31" upper_limit="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.69</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Accounted for correlation due to cross-over design and adjusted for exercise session</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>CGM Metrics During Late Recovery - Time &lt; 54 mg/dL</title>
        <description>Comparison of percentage of time &lt; 54 mg/dL from CGM between the exercise strategies.</description>
        <time_frame>90 min after the standard meal until 1200 noon the day after each exercise session</time_frame>
        <population>Included data were limited to periods with at least 12 hours of CGM data</population>
        <group_list>
          <group group_id="O1">
            <title>Control</title>
            <description>No basal insulin adjustment, no carbohydrate intake (until glucose drops &lt;70 mg/dL).</description>
          </group>
          <group group_id="O2">
            <title>Basal Insulin Reduction</title>
            <description>Basal insulin reduction to 50% 5 minutes before the start of exercise.</description>
          </group>
          <group group_id="O3">
            <title>Glucose Tabs</title>
            <description>Dextrose tabs orally (20 grams) 5 minutes before the start of exercise and at 30 minutes of exercise (total 40 grams).</description>
          </group>
          <group group_id="O4">
            <title>G-Pen Mini™ (Glucagon Injection)</title>
            <description>Glucagon (150 µg) 5 minutes before the start of exercise (SQ-abdomen).</description>
          </group>
        </group_list>
        <measure>
          <title>CGM Metrics During Late Recovery - Time &lt; 54 mg/dL</title>
          <description>Comparison of percentage of time &lt; 54 mg/dL from CGM between the exercise strategies.</description>
          <population>Included data were limited to periods with at least 12 hours of CGM data</population>
          <units>percentage</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="13"/>
                <count group_id="O3" value="13"/>
                <count group_id="O4" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3" spread="3"/>
                    <measurement group_id="O2" value="3" spread="3"/>
                    <measurement group_id="O3" value="3" spread="1"/>
                    <measurement group_id="O4" value="2" spread="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.67</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Accounted for correlation due to cross-over design and adjusted for exercise session</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>CGM Metrics During Late Recovery - Time &lt; 70 mg/dL</title>
        <description>Comparison of percentage of time &lt; 70 mg/dL from CGM between the exercise strategies.</description>
        <time_frame>90 min after the standard meal until 1200 noon the day after each exercise session</time_frame>
        <population>Included data were limited to periods with at least 12 hours of CGM data</population>
        <group_list>
          <group group_id="O1">
            <title>Control</title>
            <description>No basal insulin adjustment, no carbohydrate intake (until glucose drops &lt;70 mg/dL).</description>
          </group>
          <group group_id="O2">
            <title>Basal Insulin Reduction</title>
            <description>Basal insulin reduction to 50% 5 minutes before the start of exercise.</description>
          </group>
          <group group_id="O3">
            <title>Glucose Tabs</title>
            <description>Dextrose tabs orally (20 grams) 5 minutes before the start of exercise and at 30 minutes of exercise (total 40 grams).</description>
          </group>
          <group group_id="O4">
            <title>G-Pen Mini™ (Glucagon Injection)</title>
            <description>Glucagon (150 µg) 5 minutes before the start of exercise (SQ-abdomen).</description>
          </group>
        </group_list>
        <measure>
          <title>CGM Metrics During Late Recovery - Time &lt; 70 mg/dL</title>
          <description>Comparison of percentage of time &lt; 70 mg/dL from CGM between the exercise strategies.</description>
          <population>Included data were limited to periods with at least 12 hours of CGM data</population>
          <units>percentage</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="13"/>
                <count group_id="O3" value="13"/>
                <count group_id="O4" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10" spread="9"/>
                    <measurement group_id="O2" value="8" spread="6"/>
                    <measurement group_id="O3" value="8" spread="6"/>
                    <measurement group_id="O4" value="6" spread="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.84</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Accounted for correlation due to cross-over design and adjusted for exercise session</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>CGM Metrics During Late Recovery - Time in Range (70-180 mg/dL)</title>
        <description>Comparison of percentage of time in range (70-180 mg/dL) from CGM between the exercise strategies.</description>
        <time_frame>90 min after the standard meal until 1200 noon the day after each exercise session</time_frame>
        <population>Included data were limited to periods with at least 12 hours of CGM data</population>
        <group_list>
          <group group_id="O1">
            <title>Control</title>
            <description>No basal insulin adjustment, no carbohydrate intake (until glucose drops &lt;70 mg/dL).</description>
          </group>
          <group group_id="O2">
            <title>Basal Insulin Reduction</title>
            <description>Basal insulin reduction to 50% 5 minutes before the start of exercise.</description>
          </group>
          <group group_id="O3">
            <title>Glucose Tabs</title>
            <description>Dextrose tabs orally (20 grams) 5 minutes before the start of exercise and at 30 minutes of exercise (total 40 grams).</description>
          </group>
          <group group_id="O4">
            <title>G-Pen Mini™ (Glucagon Injection)</title>
            <description>Glucagon (150 µg) 5 minutes before the start of exercise (SQ-abdomen).</description>
          </group>
        </group_list>
        <measure>
          <title>CGM Metrics During Late Recovery - Time in Range (70-180 mg/dL)</title>
          <description>Comparison of percentage of time in range (70-180 mg/dL) from CGM between the exercise strategies.</description>
          <population>Included data were limited to periods with at least 12 hours of CGM data</population>
          <units>percentage</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="13"/>
                <count group_id="O3" value="13"/>
                <count group_id="O4" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73" spread="12"/>
                    <measurement group_id="O2" value="71" spread="10"/>
                    <measurement group_id="O3" value="69" spread="20"/>
                    <measurement group_id="O4" value="67" spread="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.63</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Accounted for correlation due to cross-over design and adjusted for exercise session</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>CGM Metrics During Late Recovery - Time &gt; 180 mg/dL</title>
        <description>Comparison of percentage of time &gt; 180 mg/dL from CGM between the exercise strategies.</description>
        <time_frame>90 min after the standard meal until 1200 noon the day after each exercise session</time_frame>
        <population>Included data were limited to periods with at least 12 hours of CGM data</population>
        <group_list>
          <group group_id="O1">
            <title>Control</title>
            <description>No basal insulin adjustment, no carbohydrate intake (until glucose drops &lt;70 mg/dL).</description>
          </group>
          <group group_id="O2">
            <title>Basal Insulin Reduction</title>
            <description>Basal insulin reduction to 50% 5 minutes before the start of exercise.</description>
          </group>
          <group group_id="O3">
            <title>Glucose Tabs</title>
            <description>Dextrose tabs orally (20 grams) 5 minutes before the start of exercise and at 30 minutes of exercise (total 40 grams).</description>
          </group>
          <group group_id="O4">
            <title>G-Pen Mini™ (Glucagon Injection)</title>
            <description>Glucagon (150 µg) 5 minutes before the start of exercise (SQ-abdomen).</description>
          </group>
        </group_list>
        <measure>
          <title>CGM Metrics During Late Recovery - Time &gt; 180 mg/dL</title>
          <description>Comparison of percentage of time &gt; 180 mg/dL from CGM between the exercise strategies.</description>
          <population>Included data were limited to periods with at least 12 hours of CGM data</population>
          <units>percentage</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="13"/>
                <count group_id="O3" value="13"/>
                <count group_id="O4" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16" spread="13"/>
                    <measurement group_id="O2" value="21" spread="12"/>
                    <measurement group_id="O3" value="23" spread="20"/>
                    <measurement group_id="O4" value="26" spread="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.24</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Accounted for correlation due to cross-over design and adjusted for exercise session</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>CGM Metrics During Late Recovery - Time &gt; 250 mg/dL</title>
        <description>Comparison of percentage of time &gt; 250 mg/dL from CGM between the exercise strategies.</description>
        <time_frame>90 min after the standard meal until 1200 noon the day after each exercise session</time_frame>
        <population>Included data were limited to periods with at least 12 hours of CGM data</population>
        <group_list>
          <group group_id="O1">
            <title>Control</title>
            <description>No basal insulin adjustment, no carbohydrate intake (until glucose drops &lt;70 mg/dL).</description>
          </group>
          <group group_id="O2">
            <title>Basal Insulin Reduction</title>
            <description>Basal insulin reduction to 50% 5 minutes before the start of exercise.</description>
          </group>
          <group group_id="O3">
            <title>Glucose Tabs</title>
            <description>Dextrose tabs orally (20 grams) 5 minutes before the start of exercise and at 30 minutes of exercise (total 40 grams).</description>
          </group>
          <group group_id="O4">
            <title>G-Pen Mini™ (Glucagon Injection)</title>
            <description>Glucagon (150 µg) 5 minutes before the start of exercise (SQ-abdomen).</description>
          </group>
        </group_list>
        <measure>
          <title>CGM Metrics During Late Recovery - Time &gt; 250 mg/dL</title>
          <description>Comparison of percentage of time &gt; 250 mg/dL from CGM between the exercise strategies.</description>
          <population>Included data were limited to periods with at least 12 hours of CGM data</population>
          <units>percentage</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="13"/>
                <count group_id="O3" value="13"/>
                <count group_id="O4" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" spread="2"/>
                    <measurement group_id="O2" value="4" spread="9"/>
                    <measurement group_id="O3" value="9" spread="17"/>
                    <measurement group_id="O4" value="5" spread="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.26</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Accounted for correlation due to cross-over design and adjusted for exercise session</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse Events (AE) were collected 12 hours prior to each exercise session, during each exercise session, and during the day after each exercise session.</time_frame>
      <desc>Hypoglycemia, hyperglycemia, injection-related, and exercise-induced events only reported as AEs when criteria below met.
Hypoglycemia: event required dextrose or glucagon to treat; Hyperglycemia: evaluation or treatment obtained from a health care provider or event involved Diabetic Ketoacidosis; Injection-related events: treatment was given; Exercise-induced events: subject falls or has signs of heart attack, poor perfusion, angina, pathologic arrhythmia, or other condition not expected</desc>
      <group_list>
        <group group_id="E1">
          <title>Control</title>
          <description>No basal insulin adjustment, no carbohydrate intake (until glucose drops &lt;70 mg/dL).</description>
        </group>
        <group group_id="E2">
          <title>Basal Insulin Reduction</title>
          <description>Basal insulin reduction to 50% 5 minutes before the start of exercise.</description>
        </group>
        <group group_id="E3">
          <title>Glucose Tabs</title>
          <description>Dextrose tabs orally (20 grams) 5 minutes before the start of exercise and at 30 minutes of exercise (total 40 grams).</description>
        </group>
        <group group_id="E4">
          <title>G-Pen Mini™ (Glucagon Injection)</title>
          <description>Glucagon (150 µg) 5 minutes before the start of exercise (SQ-abdomen).</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Stephanie DuBose</name_or_title>
      <organization>Jaeb Center for Health Research</organization>
      <phone>813.975.8690</phone>
      <email>sdubose@jaeb.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

